Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer

Stewart, Louise M.; Spilsbury, Katrina; Jordan, Susan J.; Stewart, Colin J.R.; Holman, C. DʼArcy J.; Powell, Aime; Reekie, Joanne; Cohen, Paul A.

doi:10.1016/j.canep.2018.05.011

Cited by 25 publications

(16 citation statements)

References 60 publications

(98 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, underdiagnosis of any abdominal compliant may lead to life-threatening situations such as overgrowth or torsion of ovarian masses [32] . About 70% of the patients had no parity which confirms the other studies that have been claimed low parity is related to ovarian cancer [33] . From about 30% who had childbirth, the highest percentage was related to a child with 55%.…”

Section: Discussionsupporting

confidence: 86%

Frequency of Malignant Ovarian Germ Cell Tumor and Distribution of Demographic Features in a Main Tertiary Hospital in Iran

Akhavan

Agah

Alipour

2018

J Obstet Gynecol Cancer Res

View full text Add to dashboard Cite

Identification of 19 new risk loci and potential ... [19] The significance of spermatic cord involvement by testicular germ cell tumors: Should we be staging discontinuous invasion from involved ... [20] Repair shielding of platinum-DNA lesions in testicular germ cell tumors by high-mobility group box protein 4 imparts cisplatin ... [21] Germ cell tumors of the ... [22] Management of ovarian germ ... [23] Crude and age-specific incidence rate ... [24] Incidence rate of ovarian cancer in Iran ... [25] Malignant struma ovarii: An analysis of 88 cases, including ... [26] Natural history of biologically malignant struma ... [27] Ovary: Germ cell ... [28] Age-specific ovarian cancer incidence rate ... [29] Body mass index and ... [30] Evaluation of risk factors and prognostic factors of ... [31] Malignant germ cell tumors of the ovary ... [32] Papillary serous cystadenoma of ovary: A huge ovarian cyst complicating the ... [33] Risk of high-grade serous ovarian cancer associated ... [34] Ovarian cancer complicated by pregnancy ... [35] Williams Obstetrics 22nd Edition Study ... [36] Epidemiology and etiology of infertility in Iran, systematic ...

show abstract

Section: Discussionsupporting

confidence: 86%

Frequency of Malignant Ovarian Germ Cell Tumor and Distribution of Demographic Features in a Main Tertiary Hospital in Iran

Akhavan

Agah

Alipour

2018

J Obstet Gynecol Cancer Res

View full text Add to dashboard Cite

show abstract

“…Given the likely extra-ovarian origin of a proportion of EOCs, exposures associated with tubal pathologies are of increasing interest with respect to EOC risk. Sexually transmitted infections (STIs) are associated with a range of gynecologic sequelae including pelvic inflammatory disease (PID), 6,7 PID has been associated with EOC risk, 8,9 though data to date suggest strongest associations with borderline tumors. 10 Chlamydia trachomatis and Mycoplasma genitalium are two sexually transmitted bacterial causes of PID.…”

Section: Introductionmentioning

confidence: 99%

Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort

Idahl

Cornet

Maldonado

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

A substantial proportion of epithelial ovarian cancer (EOC) arises in the fallopian tube and other epithelia of the upper genital tract; these epithelia may incur damage and neoplastic transformation after sexually transmitted infections (STI) and pelvic inflammatory disease. We investigated the hypothesis that past STI infection, particularly Chlamydia trachomatis, is associated with higher EOC risk in a nested case‐control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort including 791 cases and 1669 matched controls. Serum antibodies against C. trachomatis, Mycoplasma genitalium, herpes simplex virus type 2 (HSV‐2) and human papillomavirus (HPV) 16, 18 and 45 were assessed using multiplex fluorescent bead‐based serology. Conditional logistic regression was used to estimate relative risks (RR) and 95% confidence intervals (CI) comparing women with positive vs. negative serology. A total of 40% of the study population was seropositive to at least one STI. Positive serology to C. trachomatis Pgp3 antibodies was not associated with EOC risk overall, but with higher risk of the mucinous histotype (RR = 2.30 [95% CI = 1.22‐4.32]). Positive serology for chlamydia heat shock protein 60 (cHSP60‐1) was associated with higher risk of EOC overall (1.36 [1.13‐1.64]) and with the serous subtype (1.44 [1.12‐1.85]). None of the other evaluated STIs were associated with EOC risk overall; however, HSV‐2 was associated with higher risk of endometrioid EOC (2.35 [1.24‐4.43]). The findings of our study suggest a potential role of C. trachomatis in the carcinogenesis of serous and mucinous EOC, while HSV‐2 might promote the development of endometrioid disease.

show abstract

“…Antibodies to C. trachomatis and chsp60 is associated with pelvic inflammatory disease (PID) [19,20]. Recent studies have shown an increased risk of HGSC after PID [21,22]. During an inflammatory process, the glycoprotein mucin 1 (MUC1), normally expressed by epithelial cells, are overexpressed to provide a barrier between the epithelium and the extra cellular milieu against infections [23].…”

Section: Introductionmentioning

confidence: 99%

Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden

Jonsson

Lundin

Elgh

et al. 2020

Translational Oncology

View full text Add to dashboard Cite

BACKGROUND:Chlamydia trachomatis salpingitis causes inflammatory damage to the fallopian tube and could potentially cause initiation and progression of high-grade serous ovarian cancer (HGSC). Furthermore, C. trachomatis infection may stimulate mucin 1 (MUC1) protein production, possibly affecting anti-MUC1 antibody levels. The aim of this study was to examine if serology indicating past infection with C. trachomatis as well as anti-MUC1 production was associated with subsequent risk of HGSC. MATERIALS AND METHODS: In a prospective nested case–control study within the Northern Sweden Health and Disease Study and the Northern Sweden Maternity Cohort, the prevalence of chlamydial and anti-MUC1 antibodies was analyzed in blood samples drawn more than one year before diagnosis from 92 women with HGSC and 359 matched controls. Matching factors were age, date at blood draw, and sampling cohort. Plasma C. trachomatis IgG was analyzed using commercial micro-immunofluorescence test; chlamydial Heat Shock Protein 60 IgG (cHSP60) and anti-MUC1 IgG were analyzed with ELISA technique. RESULTS: The prevalence of C. trachomatis IgG and cHSP60 IgG antibodies, as well as the level of anti-MUC1 IgG was similar in women with HGSC and controls (16.3% vs. 17.0%, P = 0.87; 27.2% vs. 28.5%, P = 0.80; median 0.24 vs. 0.25, P = 0.70). Anti-MUC1 IgG and cHSP60 IgG levels were correlated (r = 0.169; P < 0.001). CONCLUSIONS: The findings of this prospective nested case–control study did not support an association between C. trachomatis infection, as measured by chlamydial serology, or anti-MUC1 IgG antibodies, and subsequent risk of HGSC.

show abstract

Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer

Abstract: Our finding of an increased risk of HGSC associated with PID lends support to the hypothesis that inflammatory processes may be involved in the etiology of HGSC.

Cited by 25 publications

References 60 publications

Frequency of Malignant Ovarian Germ Cell Tumor and Distribution of Demographic Features in a Main Tertiary Hospital in Iran

Frequency of Malignant Ovarian Germ Cell Tumor and Distribution of Demographic Features in a Main Tertiary Hospital in Iran

Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort

Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden

Contact Info

Product

Resources

About